Digital therapeutics will be one of the topics discussed at INVEST Digital Health scheduled for October 26 at Health Wildcatters headquarters in Pegasus Park in Dallas. Register today!

A panel discussion on the future of digital medicine highlighted some of the collaborations taking place between pharma companies and digital health, as well as some of the challenges facing the push towards mainstream implementation.

A bankruptcy court in Delaware approved a stalking-horse bid from Otsuka to acquire Proteus Digital Health for $15 million. The company, which makes sensor that can be embedded in pills to track medication adherence, filed for bankruptcy in June.

Proteus, which makes tiny sensors that can track medication adherence, will no longer develop the technology in behavioral health medications for Otsuka Pharmaceutical. Instead, the startup is shifting its focus to oncology and infectious diseases, where it hopes its tech will have better traction.

At the intersection of technology and medicine, the Digital Medicine & Medtech Showcase will offer more than 70 dedicated company presentations and 500+ attendees exclusively from the digital medicine and medtech sectors. 

Proteus’ new oral oncology drug is a digital version of capecitabine, a common chemotherapy medication often used to treat breast and gastrointestinal cancers.

Otsuka’s top U.S.-based leaders spoke about the company’s partnerships in mental health and how it is driving innovation in big pharma.

Otsuka also made an $88 million investment as part of the expansion. The companies plan to launch Abilify MyCite, approved in November 2017, by the end of this year.